Elisa Tests Market Forecasts to 2030 – Global Analysis By Type (Indirect ELISA, Sandwich ELISA, Competitive ELISA and Multiple and Portable ELISA), Technology (Chemiluminescent, Colorimetric and Fluorescent), Application, End User and By Geography

Elisa Tests Market Forecasts to 2030 – Global Analysis By Type (Indirect ELISA, Sandwich ELISA, Competitive ELISA and Multiple and Portable ELISA), Technology (Chemiluminescent, Colorimetric and Fluorescent), Application, End User and By Geography

According to Stratistics MRC, the Global Elisa Tests Market is accounted for $2.55 billion in 2023 and is expected to reach $4.64 billion by 2030 growing at a CAGR of 8.9% during the forecast period. The enzyme-linked immune sorbent assay is the standard assay technique used to identify and quantify antibodies, hormones, peptides, and proteins in the blood. The ELISA test is often used in pharmaceutical quality control tests like endotoxin assays and protein quantification and is crucial in the diagnosis of a number of viral diseases. ELISA is a diagnostic technique in plant pathology and medicine as well as a quality control checks in many different sectors. Enzyme-linked immune sorbent assay (ELISA) testing is frequently used as a quality assurance check and screening instrument in a variety of fields, including medicine and plant pathology.

According to the World Health Organization (WHO), around 37.7 million people had HIV in 2020.

Market Dynamics:

Driver:

Rising demand for early and accurate diagnosis

Effective illness management and therapy rely on early and precise diagnosis. The high sensitivity and specificity of Elisa testing enable medical personnel to identify and measure particular biomarkers in patient samples. Early diagnosis enables quick treatment beginning, which can greatly enhance patient results. Additionally, healthcare practitioners can intervene and swiftly implement effective treatment techniques by quickly recognizing these biomarkers. The market for Elisa testing is expanding due to the demand for early and accurate diagnosis.

Restraint:

Stringent government regulations

The marketing of diagnostic products is difficult because some products are categorized as medical devices even though they are intended for use in diagnostic procedures by doctors. Without successfully completing clinical trials, which are a time-consuming, expensive, and uncertain process, such devices cannot be launched. The reality that different countries have different rules for these devices' certification is a significant challenge for international corporations. Additionally, any modifications to rules made by various regulatory agencies, like the FDA, during the product development process may cause a delay in the introduction of potential products. These stringent government regulations are the major barriers to market growth.

Opportunity:

Technological developments

The market for Elisa testing has benefited from technological developments such as the creation of automated systems, the ability to multiplex and enhanced sensitivity and specificity of assays. Technological improvements have led to the creation of automated Elisa systems, excluding manual labor and enhancing efficiency. Multiple samples can be handled simultaneously by automated platforms, streamlining the testing procedure and boosting throughput. Furthermore, by speeding up turnaround times and increasing laboratory efficiency, this technology enables healthcare practitioners to efficiently perform a higher volume of tests. Elisa tests are becoming more widely used in many healthcare settings as a result of these developments, which improve their effectiveness, accuracy, and productivity, which drives market demand.

Threat:

Alternative technologies' competition

Alternative diagnostic technologies, such as point-of-care testing (POCT) devices, next-generation sequencing (NGS), and molecular diagnostic techniques (e.g., PCR), compete with Elisa tests on the market. These innovations have benefits like quicker turnaround times, greater sensitivity, and the capacity to detect multiple analytes at once. Elisa tests may be replaced or competed with as these technologies develop and become more widely available, especially in areas where molecular diagnostics have clear advantages. The market for Elisa tests may be threatened by the availability and uptake of these substitute technologies.

Covid-19 Impact

Initially, in the COVID-19 epidemic, there were no particular diagnostic tests available to identify the illness in patients. Initially, alternative diagnostic procedures were attempted, but they were not very successful. Additionally, due to the unavailability of certain COVID-19 diagnostic tests, diagnostic kit manufacturers had profitable chances to market their COVID-19 diagnostic products. Utilizing this chance, many established companies as well as a few start-ups from different nations offered COVID-19 diagnostic kits to local as well as global markets.

The sandwich ELISA segment is expected to be the largest during the forecast period

The sandwich ELISA segment is estimated to hold the largest share. Antigen is measured using a sandwich ELISA, which consists of two layers of antibodies (the capture antibody and the detection antibody). Two antigenic sites on the target antigens are ready to bind to the antibodies. In sandwich ELISA techniques, monoclonal or polyclonal antibodies are employed to capture and recognize antibodies. Sandwich ELISA works the best for detecting immunological responses, and this fact is promoting market expansion. Sandwich ELISA, which uses a variety of antibodies to bind to the same antigen for recognition or detection, is also the most sensitive test available. It also has a high degree of flexibility and higher specificity.

The infectious diseases segment is expected to have the highest CAGR during the forecast period

The infectious diseases segment is anticipated to have lucrative growth during the forecast period, due to an increase in the prevalence of chronic illnesses and infectious disorders, infectious diseases are now leading the ELISA market's application sector. HIV, HBV, HCV, HTLV, Diphtheria, Giardiasis, and several other infectious blood-borne illnesses The application sector of the enzyme-linked immune sorbent assay (ELISA) testing market is dominated by ELISA tests because they provide quick and accurate findings, have high sensitivity, are automated and simple to perform, and do not require radioactive materials or expensive radiation gear.

Region with largest share:

North America commanded the largest market share during the extrapolated period due to the highly developed healthcare system and the growing use of medical gadgets. Rising R&D expenditures by pharmaceutical firms and government organizations for disorders and diseases, including diabetes and chronic illnesses, would also contribute to the market growth for ELISA tests in this region during the projected period.

Region with highest CAGR:

Europe is expected to witness profitable growth over the projection period due to the rising disposable income and healthcare expenditure in emerging nations. The market for ELISA tests is anticipated to grow in the coming years as a result of the rising use of medical equipment in developed nations. Additionally, due to the large geriatric population and significant investment in research and development, in the projected time frame, it is also anticipated that the rising frequency of non-communicable diseases on the European continent will increase demand for ELISA testing.

Key players in the market

Some of the key players in the Elisa Tests Market include Abbott Laboratories, Danaher Corporation, BioMerieux SA, Quidel Corporation, Siemens Healthineers, Sysmex Corporation, Bio-Rad Laboratories, Ortho Clinical Diagnostics, Thermo Fisher Scientific, Inc., ZEUS Scientific, Inc., Hoffmann-La Roche AG, PerkinElmer, Inc., Enzo Life Sciences, Inc., Agilent Technologies, Inc., R&D Systems, Inc., Bruker, Eurofins Scientific, ELISA Technologies, Inc and BioLegend, Inc.

Key Developments:

In May 2023, Abbott, a global leader in health care and nutrition, has partnered with Real Madrid, one of the most successful and popular football clubs in the world, to inaugurate the Abbott-Real Madrid Innovation Lab, a space for collaboration and research on the future of sports physiology and nutrition.

In March 2023, Thermo Fisher Scientific, the world leader in serving science, and Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage cell therapy company engineering advanced chimeric antigen receptor (CAR)-T cell therapies for solid tumors, announced an update to their strategic collaboration to further the development of manufacturing processes for new cancer treatments.

In November 2020, Siemens Healthineers announced that its SARS-CoV-2 IgG Antibody Test has proven to evaluate neutralizing antibodies and has gained CE Marking. This test is the better version of its previously launched COVID-19 antibody test.

Types Covered:
• Indirect ELISA
• Sandwich ELISA
• Competitive ELISA
• Multiple and Portable ELISA

Technologies Covered:
• Chemiluminescent
• Colorimetric
• Fluorescent

Applications Covered:
• Infectious Diseases
• Protein Quantitation
• Vaccine Development
• Cancer
• Immunology
• Other Applications

End Users Covered:
• Pharmaceutical and Biotech Companies
• Academic Research Centers
• Clinical Laboratories
• Hospitals and Diagnostic Centers
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements